ClinicalTrials.gg
CompletedNCT05451667Updated Jan 4, 2023

Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers

A Phase 1 interventional study of YJ001 for Spray Use and Placebo of YJ001 for Spray Use in Safety and Tolerability, sponsored by Yuejia Pharmaceuticals (USA), Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-04.

Sponsored by Yuejia Pharmaceuticals (USA), Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This phase I, randomized, double-blind, placebo controlled study is to investigate the safety, tolerability and pharmacokinetics (PK) of topically administered YJ001 in a single-ascending dose (SAD) fashion in healthy volunteers between 18 to 55 years of age, to establish the dosage range for spray use, and to provide a dosage regimen for Phase I multiple-ascending dose (MAD) study in healthy subjects. The study is to enroll 4 cohorts, the doses of which are 148, 296, 552 and 828 mg, with the option to enroll 2 additional cohorts (8 subjects for each cohort) without requiring a protocol amendment. Subjects will be screened between Day -28 and Day -2 and will be admitted to the clinic on Day -1. Subjects will be housed within the clinic from Day -1 through Day 8 and will be discharged on Day 8 after all scheduled study procedures have been completed.

Read the detailed description

This phase I, randomized, double-blind, placebo controlled study is to investigate the safety, tolerability and pharmacokinetics (PK) of topically administered YJ001 in a single-ascending dose (SAD) fashion in healthy volunteers between 18 to 55 years of age, to establish the dosage range for spray use, and to provide a dosage regimen for Phase I multiple-ascending dose (MAD) study in healthy subjects. The study is to enroll 4 cohorts, the doses of which are 148, 296, 552 and 828 mg, with the option to enroll 2 additional cohorts (8 subjects for each cohort) without requiring a protocol amendment. Each cohort will consist of 8 subjects (6 active; 2 placebo). Each subject will be administered a single dose of YJ001 as multiple sprays (8 sprays/foot for Cohort 1, 16 sprays/foot for Cohort 2, 16 sprays/foot for Cohort 3, and 24 sprays/foot for Cohort 4) topically on both feet; and below the ankle, with the administration area set as 450 cm2 (both feet).

Safety will be evaluated by assessing incidence and severity of adverse events (AEs) and serious adverse events (SAEs); observed values and changes in baseline of clinical safety laboratory test results, 12-lead electrocardiogram (ECG), vital signs; and physical examination inclusive of skin reaction findings at the Investigational Product (IP) administration sites.

For pharmacokinetics evaluation, serial blood samples will be collected in the subjects of Cohorts 2 to 4 for up to 7 days following a single dose to assess the PK of YJ001 and metabolites in plasma. Pooled urine samples will be collected in the subjects of Cohorts 2 to 4 to evaluate renal excretion of YJ001 and metabolites.

Subjects will be screened between Day -28 and Day -2 and will be admitted to the clinic on Day -1. Subjects will be housed within the clinic from Day -1 through Day 8 and will be discharged on Day 8 after all scheduled study procedures have been completed.

02

Conditions studied

  • Safety and Tolerability
03

In context

Lead sponsor

This is the only study on the registry with Yuejia Pharmaceuticals (USA), Inc. as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, between the ages of 18-55 years at screening, both inclusive.
  2. Subjects voluntarily consenting for participation in the study and have signed document. Subjects are required to understand verbal and/or written English or any other language in which a certified translation of the informed consent is available.
  3. The body weight of male and female should be ≥ 50.0 and ≥ 45.0 kg, respectively; have a (BMI) between 19.0 to 32.0 kg/m2 (both inclusive) at screening, calculated as weight (kg)/height2 (m2). Subjects must have two feet. Each foot must have five digits. Each foot must have at least total surface area of 450 cm2 measured from below the ankle to the toes including both dorsum and plantar areas.
  4. Medical history without any pathology/surgery in the last 6 months.
  5. Resting supine blood pressure 90-140 (systolic)/60-90 (diastolic) mmHg, a resting pulse rate of 45-100 beats per minute at screening.
  6. Calculated should be within the normal range using Chronic Kidney Disease Epidemiology Collaboration () Creatinine Based Equation1.
  7. Computerized 12-lead recording without signs of clinically significant pathology or showing no clinically significant deviation as judged by the Investigator at screening and pre-dose.
  8. Subjects with either C-reactive protein of up to 3.0 mg/L or of up to 5.9%.
  9. Males must not to donate sperm until 90 days after last dose of study drug and must be willing to use a condom during heterosexual activity for up to 90 days after the application of the study drug.
  10. Females must be either for at least 1 year, surgically sterile (bilateral tubal ligation [including clip, cauterization methods and coil], bilateral oophorectomy or hysterectomy, and needs to be confirmed follicle stimulating hormone [FSH] level >40 IU/L), or of either practicing true abstinence or practicing 2 effective means of for 3 weeks prior to study drug administration, and until 28 days after study drug administration:

    1. Intrauterine device (IUD) or IUD hormone-releasing system.
    2. Combined estrogen and progestogen containing hormonal contraception (oral, intravaginal, or transdermal) associated with inhibition of ovulation.
    3. Progesterone-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation.
    4. Intrauterine hormone-releasing system.
    5. Double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicide).
  11. All values of hematology and biochemistry of blood and urine are within allowed normal limits or not clinically significant as judged by the Investigator.
  12. Able and willing to comply with all study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Current participation in another drug or device study or treated with an investigational drug within 30 days or 5 half-lives, whichever is longer, before dosing.
  2. History/evidence of pathology related to cardiovascular (CVS), central nervous system (CNS), respiratory tract, gastrointestinal (GI), endocrinology, immunology, hematology, or any other systemic disorder/major surgeries within the last 6 months that in the opinion of the Investigator would confound subject's participation and follow-up in the clinical trial.
  3. History of clinically significant drug, food allergy, skin allergy, or sensitivity to drugs of the same class (e.g., 5-aminosalicylic acid, sulfasalazine, and salicylates) or known to YJ001 or any of its components.
  4. History of asthma. Adults with history of benign (resolved) childhood asthma may be included.
  5. Consumed more than 28 units of ethanol per week at any time in the 6 months before dosing (1 unit of ethanol is equivalent to 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of spirits) or history of drug or alcohol abuse within the 6 months or evidence of such abuse as indicated by inquiry, medical history or the laboratory assays conducted during screening.
  6. Positive screening or check-in alcohol/drugs of abuse/cotinine screen.
  7. Positive test results for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening. SARS-CoV-2 testing will be either NP or nasal swab PCR performed at Day -4, and in accordance with Centers for Disease Control and Prevention (CDC), FDA and local health authorities at the time of enrollment for this study. Participants not willing to comply with Pharmaron's COVID 19 policy.
  8. Female volunteers who are pregnant or lactating.
  9. Systemic or topical use of aspirin or salicylic acid containing products or sulfasalazine/salicylic acid derivatives within 14 days of study drug dosing.
  10. Use of other prescription and non-prescription medications (with the exception of oral , combined estrogen and progestogen containing hormonal contraception and progestogen-only hormonal contraception), including nonsteroidal anti-inflammatory drugs, NSAIDs (i.e., ibuprofen), blood thinners, or sucralfate or herbal preparations within 14 days or 5 half-lives (whichever is longer) before study drug dosing, or use of an over-the-counter medication, vitamins, or supplements (including fish liver oils) within 14 days before study drug dosing.
  11. Any subject who has received any known hepatic or renal clearance (CLr) altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazines, or herbal/plant-derived preparations such as St. John's Wort, etc.) for a period of 30 days prior to the dose of study medication.
  12. Positive screen on , , or (HIV) at the time of screening evaluations.
  13. Unwilling to stay in the clinical unit for the required duration as per the protocol or consume the standard meal to be provided as per the protocol.
  14. History of blood donation of more than 500 mL in the last 2 months prior to screening.
  15. Consumption of xanthine containing food or beverages (like tea, coffee, chocolates, or cola drinks) 24 hours prior to dosing.
  16. Any subject who consumes more than 5 cigarettes per day within 30 days before study drug dosing or who cannot stop using any tobacco- or nicotine-containing product during the duration of the trial.
  17. History or evidence of poor venous access.
  18. History of bleeding disorders.
  19. Any other medical, psychological, or social condition which, in the opinion of the Investigator, would prevent the subject from fully participating in the study, would represent a concern for study compliance, or would constitute a safety concern to the subject.
  20. Presence of skin disorders, tattoos, or other skin conditions on either foot that may interfere with the objectives of the study (as per investigator evaluation).
  21. Use of any kind of topical lotions on the feet for 72 hours prior to the study that may interfere with the objectives of the study (as per investigator evaluation).
  22. An employee of the study center or Sponsor or family member of a study center employee.
  23. Have a significant acute illness within 7 days prior to study drug administration or have had a major illness or hospitalization within 1 month prior to study drug administration.
  24. Any subject considering or scheduled to undergo any surgical procedure from screening to follow-up visit.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Cohort 1 (6 active, 2 placebo)

    148 mg

    Drug: YJ001 for Spray Use · Drug: Placebo of YJ001 for Spray Use

  • Experimental
    Cohort 2 (6 active, 2 placebo)

    296 mg

    Drug: YJ001 for Spray Use · Drug: Placebo of YJ001 for Spray Use

  • Experimental
    Cohort 3 (6 active, 2 placebo)

    552 mg

    Drug: YJ001 for Spray Use · Drug: Placebo of YJ001 for Spray Use

  • Experimental
    Cohort 4 (6 active, 2 placebo)

    828 mg

    Drug: YJ001 for Spray Use · Drug: Placebo of YJ001 for Spray Use

Interventions

  • YJ001 (active ingredient)

    Also known as: YJ001

  • DrugPlacebo of YJ001 for Spray Use

    Hydroxypropyl Methylcellulose

    Also known as: Hydroxypropyl Methylcellulose

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events and significant laboratory abnormality

    If ≥ 2 subjects assigned to YJ001 in a cohort experience any of the following: 1. A Grade ≥ 2 adverse event. 2. A Grade ≥ 2 clinically significant laboratory abnormality.

    Time frame: Day -28 to Day 8

  2. Systemic exposure of the 4 analytes to be assayed

    If ≥ 1 subject meets/exceeds the exposure limits for any of YJ001 and its metabolites (YJ001-A, YJ001-B, and/or YJ001-C) or if subjects are expected to exceed the specific exposure limits for any analyte at a next planned dose level.

    Time frame: Day 1 to Day 8

07

Study locations

1 site
  • Pharmaron CPC, Inc.
    Baltimore, Maryland 21201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Dec 2022, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 11, 2022
StartActual
Aug 15, 2022
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Last update
Jan 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05451667
Lead sponsor
Yuejia Pharmaceuticals (USA), Inc.
Collaborators
Zhejiang Yuejia Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Aug 15, 2022
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Last update
Jan 4, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YJ001

Start the discussion